where are we going?

Price: 88/89 cents. On May 4, cash was $19 mill.

Febr 9: "Since November 2003 the Company has been enrolling participants in a double-blind 300-patient Phase 2b human clinical trial of AOD9604 at 5 centres in Australia, assessing weight loss over three months daily oral dosing. Results are scheduled to be released in
Q3 2004".

Enrolling of some 300 odd patients can take some time: On April 7, 225 patients had been enrolled. Say that the 300 patients would have been fully enrolled by May 20?

I suppose a statement to that effect would be issued?

The trial is for 3 months only, so should finish on say Aug. 20.

However a number of patients should by now have completed the course, since the first patient was enrolled in Nov.

The trial is therefore entering an interesting phase.

Info on MBP:
http://www.hotcopper.com.au/post_thread.asp?fid=1&tid=52191&sym=MBP#130595


Gerry
Readers, please do your own research and you decide if and when to buy, hold or sell any stocks. Investment in Biotechs involves risk.